Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:TSRO
Date7/2012
Raised
Post IPO Valuation$86.3M

General Information

Websitetesarobio.com
CategoryBioTech
Phone339.970.0900
Emailcontact@tesarobio...
Employees
Founded3/2010

Offices

Waltham, USA
1000 Winter St
Suite #3300
Waltham, MA, 02451
USA

People

Co-Founder, CEO
CFO
President, CSO and co-founder
Board Member
Board of Directors
Board Observer
Chairman
Board Observer

Funding

TOTAL $161M
FUNDING TOTAL $161M
Series A, 5/2010
New Enterprise Associates
$60M
Series B, 6/2011
Kleiner Perkins Caufield & Byers
New Enterprise Associates
InterWest Partners
T. Rowe Price
Pappas Ventures
$101M
POST IPO FUNDING
Post IPO Equity, 3/2013
$91M

Tags

TESARO

Founded in 2010, TESARO is a privately held oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients. The Company intends to leverage the experience and competencies of its management team to identify, acquire and develop promising drug candidates; and to commercialize safer and more effective products for the treatment and support of cancer patients. TESARO is developing rolapitant, a potent, selective neurokinin-1 receptor antagonist that has completed Phase 2 clinical testing for the prevention of chemotherapy induced nausea and vomiting, and is advancing its ALK inhibitor program for oncology indications. Phase 3 clinical testing of rolapitant is planned to commence during 2011 and the first ALK inhibitor clinical trial is targeted to begin in 2012. TESARO was co-founded by former executives of MGI PHARMA, an oncology and acute-care focused biopharmaceutical company that Eisai Co., Ltd. acquired in 2008 for $3.9 billion. TESARO is headquartered in Waltham, Massachusetts.

Recent Milestones

  • Dollar
    TESARO received $91M in Post IPO Equity funding. (3/6/13)
    Posted 3/6/13 at 6:19pm via fiercebiotech.com
  • Stock
    Went public with stock symbol NASDAQ:TSRO. (7/6/12)
    Posted 3/23/12 at 6:02pm
  • Check
    TESARO — Tesaro seeks $86.2M IPO (3/26/12)
    Posted 3/26/12 at 6:47pm via masshightech.com
  • Dollar
    TESARO received $101M in Series B funding. (6/21/11)
    Posted 6/21/11 at 6:15pm via finsmes.com
  • Check
    TESARO — landed an exclusive licensing deal with Amgen Inc., in which the Boston company will hold rights to Amgen’s Anaplastic Lymphoma Kinase (ALK) technology (3/22/11)
    Posted 3/22/11 at 7:25am via masshightech.com
  • Check
    TESARO — has signed a deal with Miami-based OPKO Health Inc. that will bring the Boston firm exclusive rights to develop, manufacture, commercialize and distribute rolapitant, a cancer-related treatment (12/14/10)
    Posted 12/15/10 at 5:34am via masshightech.com
  • Dollar
    TESARO received $60M in Series A funding. (5/28/10)
    Posted 5/28/10 at 7:03pm via onbiovc.com
  • Check
    TESARO added Lonnie Moulde as Co-Founder, CEO.
    Posted 5/28/10 at 7:03pm
  • Check
    TESARO added Mary Lynne Hedley as President, CSO and co-founder.
    Posted 5/28/10 at 7:03pm
  • Check
    TESARO added Rick Rodgers as CFO.
    Posted 5/28/10 at 7:03pm

Videos

Screenshots

TESARO screenshot
Above: Home Page
Uploaded: 5/29/10

Stock Price

Sources

  1. Tesaro, Inc.: Series A $60M (onbiovc.com) [edit]
  2. TESARO Secures $101M in Series B Financing (finsmes.com) [edit]
  3. Tesaro pockets $91M in big financing as major cancer trials continue (fiercebiotech.com) [edit]
  4. Biotech startup Tesaro lands licensing deal for cancer treatment (masshightech.com) [edit]
    Tesaro buys rights to Amgen lung cancer tech program (masshightech.com) [edit]
    Tesaro seeks $86.2M IPO (masshightech.com) [edit]
Edit This Page
Last Edited 2/22/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy